Article Sidebar
Views PDF: 143
TREATMENT OF BENIGN PROSTATE HYPERPLASIA USING N-BUTYL CYANOACRYLATE: SUITABLE ALTERNATIVE FOR PARTICLES
Main Article Content
Abstract
Objective: To evaluate the safety and short-term outcome of prostatic artery embolization (PAE) using N-butyl cyanoacrylate (NBCA) in the treatment of benign prostatic hyperplasia (BPH) with lower urinary tract symptoms. Subjects and methods: A single-centre retrospective study on 15 patients (mean age, 65 ± 20.5 years; 45 - 85 years old) who underwent PAE with a mixture of NBCA and lipiodol (ratio from 1:4 - 1:8) for the treatment of BPH from June 2022 to September 2022. Result: The mean of total volume of NBCA/Lipiodol was 1.2 ± 0.3 ml, the total NBCA injection time was 20.5 ± 3.4 seconds, and the total radiation dose was 15,554 ± 14,397 mGy·cm. Statistically significant improvements in IPSS score, QoL quality of life score and prostate volume at one month after PAE. No major complications were noted. The International Index of Erectile Function did not change significantly. Conclusion: Prostate artery embolization by NBCA for treatment of symptomatic BPH is feasible, safe, rapid and effective.
Article Details
Keywords
Male. Lower urinary tract symptoms. Prostatic hyperplasia. Embolisation, N-butyl cyanoacrylate.
References
2. Improvement of urinary tract symptoms and quality of life in benign prostate hyperplasia patients associated with consumption of a newly developed whole tomato-based food supplement: a phase II prospective, randomized double-blinded, placebo-controlled study | Journal of Translational Medicine | Full Text. Accessed December 19, 2022. https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02684-3
3. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial | The BMJ. Accessed December 19, 2022. https://www.bmj.com/content/361/ bmj.k2338.full
4. Safety and efficacy of transcatheter embolization with Glubran®2 cyanoacrylate glue for acute arterial bleeding: a single-center experience with 104 patients | SpringerLink. Accessed December 19, 2022. https://link.springer.com/article/10.1007/s00261-017-1267-4
5. Carnevale FC, Moreira AM, de Assis AM, et al. Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: 10 Years’ Experience. Radiology. 2020;296(2):444-451. doi:10.1148/radiol.2020191249
6. Ten-year experience with arterial embolization for peptic ulcer bleeding: N-butyl cyanoacrylate glue versus other embolic agents | SpringerLink. Accessed December 19, 2022. https://link.springer.com/article/ 10.1007/s00330-020-07427-y
7. Loffroy R, Guillen K, Salet E, et al. Prostate artery embolization using n-butyl cyanoacrylate glue for urinary tract symptoms due to benign prostatic hyperplasia: a valid alternative to microparticles? J Clin Med. 2021;10(14):3161.
8. Salet E, Crombé A, Grenier N, et al. Prostatic artery embolization for benign prostatic obstruction: single-centre retrospective study comparing microspheres versus n-butyl cyanoacrylate. Cardiovasc Intervent Radiol. 2022; 45(6):814-823.
9. Randomised comparison of uterine artery embolisation (UAE) with surgical treatment in patients with symptomatic uterine fibroids (REST trial): 5-year results - PubMed. Accessed December 19, 2022. https://pubmed.ncbi.nlm.nih.gov/21481151/
10. Malling B, Røder MA, Brasso K, Forman J, Taudorf M, Lönn L. Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Radiol. 2019; 29(1):287-298. doi:10.1007/s00330-018-5564-2